Dr Reddy's Laboratories Inventory 2010-2024 | RDY

Dr Reddy's Laboratories inventory from 2010 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.
  • Dr Reddy's Laboratories inventory for the quarter ending June 30, 2024 was $0.823B, a 28.79% increase year-over-year.
  • Dr Reddy's Laboratories inventory for 2024 was $0.763B, a 28.89% increase from 2023.
  • Dr Reddy's Laboratories inventory for 2023 was $0.592B, a 11.77% decline from 2022.
  • Dr Reddy's Laboratories inventory for 2022 was $0.671B, a 8.05% increase from 2021.
Dr Reddy's Laboratories Annual Inventory
(Millions of US $)
2024 $763
2023 $592
2022 $671
2021 $621
2020 $465
2019 $486
2018 $447
2017 $440
2016 $386
2015 $410
2014 $400
2013 $396
2012 $380
2011 $361
2010 $297
2009 $
Dr Reddy's Laboratories Quarterly Inventory
(Millions of US $)
2024-06-30 $823
2024-03-31 $763
2023-12-31 $731
2023-09-30 $681
2023-06-30 $639
2023-03-31 $592
2022-12-31 $596
2022-09-30 $603
2022-06-30 $656
2022-03-31 $671
2021-12-31 $668
2021-09-30 $671
2021-06-30 $683
2021-03-31 $621
2020-12-31 $607
2020-09-30 $559
2020-06-30 $518
2020-03-31 $465
2019-12-31 $529
2019-09-30 $496
2019-06-30 $510
2019-03-31 $486
2018-12-31 $487
2018-09-30 $448
2018-06-30 $460
2018-03-31 $447
2017-12-31 $420
2017-09-30 $413
2017-06-30 $435
2017-03-31 $440
2016-12-31 $442
2016-09-30 $428
2016-06-30 $414
2016-03-31 $386
2015-12-31 $403
2015-09-30 $414
2015-06-30 $411
2015-03-31 $410
2014-12-31 $461
2014-09-30 $454
2014-06-30 $422
2014-03-31 $400
2013-12-31 $390
2013-09-30 $381
2013-06-30 $379
2013-03-31 $396
2012-12-31 $429
2012-09-30 $414
2012-06-30 $370
2012-03-31 $380
2011-12-31 $369
2011-09-30 $379
2011-06-30 $390
2011-03-31 $361
2010-12-31 $340
2010-09-30 $317
2010-06-30 $311
2010-03-31 $297
2009-12-31 $278
2009-09-30 $272
2009-06-30 $292
2009-03-31 $260
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $13.079B $3.350B
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.120B 6.83
BridgeBio Pharma (BBIO) United States $5.045B 0.00
Bausch Health Cos (BHC) Canada $2.956B 2.23
Amphastar Pharmaceuticals (AMPH) United States $2.438B 13.65
Supernus Pharmaceuticals (SUPN) United States $1.771B 357.00
Taysha Gene Therapies (TSHA) United States $0.449B 73.00
Personalis (PSNL) United States $0.315B 0.00
Assembly Biosciences (ASMB) United States $0.117B 0.00
Acasti Pharma (ACST) Canada $0.028B 0.00
Sol-Gel Technologies (SLGL) Israel $0.020B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00